Novel Nomogram Effectively Estimates Risk of Sentinel Node Metastases in Melanoma

Source: OncLive, September 2020

The Melanoma Institute Australia (MIA) nomogram was found to accurately estimate the risk of sentinel node metastasis positivity in patients with melanoma and its use could help to reduce the rate of unnecessary invasive biopsies without sacrificing sensitivity, according to results from a study published in the Journal of Clinical Oncology.1

While the Memorial Sloan Kettering Cancer Center (MSKCC) online nomogram model had a predictive accuracy of 67.7% (95% confidence interval [CI], 65.3%-70.0%), the MIA model had a higher rate of 73.9% (95% CI, 71.9%-75.9%); this translated to a 9.2% increase in accuracy comparted with the MSKCC model (P < 0.001).

Of the patients with sentinel node negativity (n = 2748), a biopsy would not have been offered to 22.1% (n = 608) based on the MIA model, 13.4% (n = 359) based on the MSKCC model, and 12.4% (n = 332) based on the National Comprehensive Cancer Network (NCCN) or ASCO/ Society of Surgical Oncology (SSO; T2+) criteria. External validation created a C-statistic of 75.0% (95% CI, 73.2%-76.7%).